SOLARA
Solara Active Pharma Sciences Limited (SOLARA) Stock Analysis
Solara Active Pharma Sciences Limited manufactures active pharmaceutical ingredients and formulations for global generics markets. It supplies APIs across therapeutic areas with USFDA-approved facilities in India. The company was formed from the demerger of Aurobindo's API business. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹644.40
-9.86% 1W | +14.80% 52W
Market Cap
3.1k CR
P/E Ratio
–
52W High
₹774
52W Low
₹422
Div. Yield
0%
Beta
0.9
50 DMA
₹637.7
200 DMA
₹546.8
Profit Margin
-0.1%
Inst. Own.
16.6%
📊 CONSOLIDATION
📉 CONSOLIDATING DOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 352 | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 | 349 | 387 | 382 |
| Expenses | 333 | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 | 312 | 330 | 320 |
| Operating Profit | 19 | 38 | -162 | 10 | 42 | 61 | 58 | 45 | 57 | 35 | 37 | 58 | 62 |
| OPM % | 5% | 9% | -76% | 3.3% | 12% | 18% | 19% | 17% | 18% | 11% | 11% | 15% | 16% |
| Other Income | 2 | -4 | -62 | -120 | 1 | 0 | 1 | 6 | 1 | 0 | -7 | 6 | 3 |
| Interest | 25 | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 | 22 | 28 | 22 |
| Depreciation | 26 | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 26 | 26 | 27 |
| Profit before tax | -29 | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 |
| Tax % | -35% | 0% | 0% | 53% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -19 | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 |
| EPS in Rs | -4.07 | -3.58 | -57.36 | -53.20 | -3.74 | 2.22 | 2.24 | -0.58 | 2.91 | -2.79 | -4.82 | 2.65 | 3.38 |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | 1,431 |
| Expenses | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,182 | 1,240 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 187 | 192 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 14% | 13% |
| Other Income | 2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 0 | 2 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 95 | 92 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 100 | 103 |
| Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | -7 | -2 |
| Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | 0% | 0% | |
| Net Profit | 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | -7 | -2 |
| EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | 0.15 | -2.05 | -1.58 | |
| Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -2.0% | -3.0% | – |
| Profit CAGR | 25.0% | – | – |
Shareholding Pattern
Promoters42.01%
FIIs14.25%
DIIs2.62%
Public41.10%
Promoters42.01%
FIIs13.58%
DIIs2.69%
Public41.71%
Promoters42.00%
FIIs11.98%
DIIs3.64%
Public42.37%
Promoters42.00%
FIIs11.59%
DIIs3.75%
Public42.66%
Promoters41.93%
FIIs11.52%
DIIs3.74%
Public42.79%
Promoters40.98%
FIIs19.30%
DIIs2.75%
Public36.95%
Promoters30.49%
FIIs15.80%
DIIs2.97%
Public50.73%
Promoters37.94%
FIIs14.63%
DIIs2.61%
Public44.82%
Promoters42.00%
FIIs11.59%
DIIs3.75%
Public42.66%
Promoters41.93%
FIIs11.52%
DIIs3.74%
Public42.79%
SOLARA
Holdings Analysis
Key strengths & risk signals
53
Overall
28
Fundamental
79
Technical
Risks (2)
Cannot calculate PEG - insufficient growth data.
WEAK MOMENTUM! Limited price growth - -9.9% (1 week), -6.7% (1 month), 13.3% (3 months).
Strengths (3)
BULLISH TREND! 50-day average (637.7) is above 200-day average (546.8) - positive signal.
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 636,329 vs down days: 329,302. Ratio: 1.93x
STRONG POSITION! Current price (644.4) is above both moving averages.
Fundamental & Technical Analysis
53Overall
28Fundamental
79Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -1.2% (DECLINING, 2/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -0.1% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 43.16% public ownership - higher volatility risk.
Stability Index
4/10
CAREFUL! Company does not have stable profit track. 2 loss-making quarters detected.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (637.7) is above 200-day average (546.8) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (644.4) is above both moving averages.
Trend Pattern
10/20
Current trend: CONSOLIDATING DOWN
52W Performance
6/10
POSITIVE YEAR! Stock gained 14.8% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 636,329 vs down days: 329,302. Ratio: 1.93x
RSI
3/5
NEUTRAL! RSI at 40.4 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 63.2% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -9.9% (1 week), -6.7% (1 month), 13.3% (3 months).
Beta
4/5
BELOW MARKET! Beta of 0.90 - slightly less volatile than market.
SOLARA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-07-29 | Concall PDF | |
| Q3FY262026-02-10 | Concall PDF | |
| Q2FY262025-11-11 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLARA | ₹644.40 | – | -0.1% | -1.2% | – | +14.8% | 53 | CONSOLIDATING DOWN | +55.2% | +69.8% | +19.5% | -1.5% |
| INDSWFTLAB | ₹360.90 | 53.9 | 8.5% | -19.7% | -3.2% | +249.6% | 59 | BREAKDOWN | +180.7% | +63.6% | +21.0% | +12.8% |
| HIKAL | ₹213.70 | – | -1.9% | -5.4% | – | -9.2% | 52 | CONSOLIDATING DOWN | -67.0% | -151.4% | +7.7% | -22.7% |
| UNICHEMLAB | ₹531.10 | 12.3 | 13.2% | 18.4% | – | +12.3% | 64 | BREAKDOWN | -495.2% | +280.7% | +20.1% | +10.0% |
| AARTIDRUGS | ₹413.30 | 19.7 | 7.1% | -2.3% | 5.4% | -17.9% | 57 | BOUNCE FROM SUPPORT | -6.9% | -9.1% | +19.0% | -2.4% |
| SAKAR | ₹1,011.50 | 72.3 | 13.3% | 22.0% | 23.0% | +184.6% | 78 | BREAKDOWN | +112.8% | -9.1% | +38.5% | +2.7% |
| SYNCOMF | ₹23.30 | 24.8 | 17.2% | 29.4% | 56.2% | +38.7% | 84 | BREAKOUT | +57.0% | -1.6% | +7.4% | -7.3% |
| VENUSREM | ₹1,719.50 | 22.4 | 13.4% | 11.6% | 57.0% | +264.9% | 74 | BREAKDOWN | +126.2% | +85.5% | +31.2% | +43.9% |
Data from TradeAlone · Updated daily
